AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth CareGeographicals
Anemia, Sickle CellTransplantation, AutologousSickle Cell TraitHematopoietic Stem Cell TransplantationHemoglobin, SickleTransplantation, HomologousBone Marrow TransplantationFetal BloodTransplantation ConditioningHematopoietic Stem Cell MobilizationHodgkin DiseaseSpinal CordRecurrenceMultiple MyelomaErythrocytes, AbnormalTreatment OutcomeAntisickling AgentsHemoglobin SC DiseaseRetrospective StudiesSurvival AnalysisFetal HemoglobinSpinal Cord InjuriesKidney TransplantationBlood Transfusion, AutologousTransplantsHydroxyureaThalassemiaGraft SurvivalUmbilical CordInfant, NewbornBlood BanksGraft RejectionAntigens, CD34beta-ThalassemiaErythrocytesHemoglobinopathiesTissue DonorsImmunosuppressive AgentsTime FactorsHematopoietic Stem CellsBlood TransfusionHemoglobinsJamaicaAcute Chest SyndromeHemoglobin C DiseaseHeart TransplantationPregnancyHemoglobin AHistocompatibility TestingTransplantationalpha-ThalassemiaCells, CulturedHemolysisGraft vs Host DiseaseLung TransplantationStem Cell TransplantationHemoglobins, AbnormalLeg UlcerGlobinsExchange Transfusion, Whole BloodFollow-Up StudiesCell SeparationErythrocyte DeformabilityHemoglobin CProspective StudiesFlow CytometryPainCord Blood Stem Cell TransplantationPostoperative ComplicationsHematologic NeoplasmsT-LymphocytesImmunosuppressionCyclosporineErythrocyte CountBlood Cell CountRisk FactorsCombined Modality TherapyCell DifferentiationTissue and Organ ProcurementFetal Tissue TransplantationTacrolimusMaternal-Fetal ExchangeAcute DiseaseVascular DiseasesAntigens, CDTransplantation ChimeraSplenic InfarctionHLA AntigensImmunophenotypingCytomegalovirus InfectionsLiving DonorsSpinal Cord DiseasesErythrocyte TransfusionErythrocyte AgingColony-Forming Units AssayLeukocytes, MononuclearLymphocyte ActivationPeripheral Blood Stem Cell TransplantationCell Culture TechniquesBiological Markers
TransplantationPost-transplant cyclophosphamideUmbilicalBone marrowGraft-versus-DonorHSCTMyelodysplasticPeripheral bloodDonorsTherapiesFludarabineAnemia2017GVHDPluripotent cellsMarrowRisksInfectionThoracicLumbarPatientsDepletionRegenerativeClinical2019UndergoOutcomesTreatmentsChronicIncludeDiseaseLeukemiaRecipientProductionUnitsDiseasesSpecific
Transplantation27
Post-transplant cyclophosphamide1
  • All patients received a conditioning backbone based on treosulfan and fludarabine, with post-transplant cyclophosphamide (PTCy) and sirolimus as graft-versus-host disease (GvHD) prophylaxis. (bvsalud.org)
Umbilical2
Bone marrow12
  • It is most often performed for patients with certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia. (wikipedia.org)
  • The patient is then treated with high-dose chemotherapy with or without radiotherapy with the intention of eradicating the patient's malignant cell population at the cost of partial or complete bone marrow ablation (destruction of patient's bone marrow's ability to grow new blood cells). (wikipedia.org)
  • While numerous teams continue to refine and expand the role of bone marrow and cord blood stem cells for their vanguard uses in blood and immune disorders, many others are looking to expand the uses of the various types of stem cells found in bone marrow and cord blood, in particular mesenchymal stem cells, to uses beyond those that could be corrected by replacing cells in their own lineage. (biomedcentral.com)
  • There are many studies involving autologous therapies and some allogenic therapies, based on the recovery of mobilized bone marrow cells, including mesenchymal stem cells (MSCs) and adipose derived stem cells that also include the stromal or adherent cell type that has an MSC phenotype. (biomedcentral.com)
  • A significant proportion of clinical studies that are underway involve bone marrow and cord blood stem cells for blood and immune disorders [ 3 ] and cancers. (biomedcentral.com)
  • The use of patient's own bone marrow aspirates, hematopoietic stem cells and MSCs, for heart muscle tissue repair can be puzzling because these cells do not normally contribute to the cardiac lineage types that are desired. (biomedcentral.com)
  • We analyzed 184 consecutive first matched related donor bone marrow transplants for thalassemia using G-CSF-primed bone marrow over 6 years from March 2017 to April 2023 across 2 centers in India. (bvsalud.org)
  • Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. (medscape.com)
  • Bone marrow aspirate demonstrating plasma cells of multiple myeloma. (medscape.com)
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines also recommend the use of serum free light chain assay and plasma cell fluorescence in situ hybridization (FISH) on bone marrow: del 13, del 17p13, t(4;14), t(11;14), t(14;16), t(14;20), 1q21 amplification, 1p deletion as part of the initial diagnostic workup. (medscape.com)
  • The clinical presentation of patients with aplastic anemia includes symptoms related to the decrease in bone marrow production of hematopoietic cells (see the image below). (medscape.com)
  • Low power, H and E showing a hypocellular bone marrow with increased adipose tissue and decreased hematopoietic cells in the marrow space. (medscape.com)
Graft-versus-2
  • This includes bone and cartilage repair, cell types into which MSCs readily differentiate, and immune conditions such as graft versus host disease and autoimmune conditions that utilize the MSC's immune suppressive properties. (biomedcentral.com)
  • My principle research interests are in the prevention and therapy of graft-versus-host disease (GVHD) and in the use of graft-versus-leukemia to eradicate blood disorders. (harvard.edu)
Donor4
HSCT4
  • Although outcomes after HSCT have improved markedly since transplants were first utilized, infection remains an important source of morbidity. (medscape.com)
  • Non-myeloablative, so-called mini transplant (microtransplantation) procedures, have been developed requiring smaller doses of preparative chemotherapy and radiation therapy, allowing HSCT to be conducted in the elderly and other patients who would otherwise be considered too weak to withstand a conventional treatment regimen. (wikipedia.org)
  • Autologous HSCT requires the extraction (apheresis) of hematopoietic stem cells (HSCs) from the patient and storage of the harvested cells in a freezer. (wikipedia.org)
  • These advantages have established autologous HSCT as one of the standard second-line treatments for such diseases as lymphoma. (wikipedia.org)
Myelodysplastic1
  • Other conditions treated with stem cell transplants include sickle cell disease, myelodysplastic syndrome, neuroblastoma, lymphoma, Ewing's sarcoma, desmoplastic small round cell tumor, chronic granulomatous disease, Hodgkin's disease and Wiskott-Aldrich syndrome. (wikipedia.org)
Peripheral blood3
Donors2
  • Donors for allogeneic transplants may be related or unrelated to the recipient. (medscape.com)
  • With more than 6,000 transplants of cord blood from related and unrelated donors performed thus far, cord blood has emerged as an acceptable, alternative source of HPCs that has some advantages over adult sources of HPCs and the availability of which represents an important development in the field. (nationalacademies.org)
Therapies1
  • There has been a rapid surge in clinical trials involving stem cell therapies over the last two to three years and those trials are establishing the clinical pathways for an emergent new medicine. (biomedcentral.com)
Fludarabine1
  • Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active. (harvard.edu)
Anemia1
  • Candidates for HSCTs include pediatric cases where the patient has an inborn defect such as severe combined immunodeficiency or congenital neutropenia with defective stem cells, and also children or adults with aplastic anemia who have lost their stem cells after birth. (wikipedia.org)
20174
GVHD2
  • In GVHD, the donated stem cells view the recipient cells as foreign and attack recipient cells. (medscape.com)
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
Pluripotent cells2
  • At the same time, the first three trials using cells derived from pluripotent cells have begun. (biomedcentral.com)
  • Aspen is built on Loring's research at the Scripps Research Institute and the PluriTest , an assay she developed after discovering that pluripotent cells have a distinct genetic signature. (blogspot.com)
Marrow4
Risks1
  • With increased knowledge of the biological characterization of AML, better prediction of transplant risks and more profound and standardized minimal residual disease (MRD) monitoring, pharmacological, and immunological strategies to prevent relapse are been developed. (bvsalud.org)
Infection1
  • Autologous transplants have the advantage of lower risk of infection during the immune-compromised portion of the treatment, since the recovery of immune function is rapid. (wikipedia.org)
Thoracic1
  • Spinal Cord Stimulation: Thoracic and Lumbar Trial -- 16. (nshealth.ca)
Lumbar1
Patients3
  • RESULTS: At transplant all patients were transfusion-dependent and had splenomegaly (median bipolar diameter by ultrasound: 20.75 cm). (bvsalud.org)
  • Such (immunosuppression) treatment, which can last for a year or more to ensure a patient's immune system doesn't react to the transplant, can make patients more susceptible to viral diseases and cancer. (blogspot.com)
  • MM is often discovered through routine blood screening when patients are being evaluated for unrelated problems. (medscape.com)
Depletion1
  • However, T-cell depletion is associated with higher rates of graft rejection and increased vulnerability to viral and fungal infections while the T-cell population is diminished. (medscape.com)
Regenerative1
  • This book also has a dedicated section on Regenerative Medicine with chapters on platelet rich plasma, stem cell therapy, and intradiscal regenerative therapy. (nshealth.ca)
Clinical4
  • In recent years, clinical trials with stem cells have taken the emerging field in many new directions. (biomedcentral.com)
  • The rapid advance of stem cell clinical trials for a broad spectrum of conditions warrants an update of the review by Trounson (2009) [ 1 ]. (biomedcentral.com)
  • Placenta-derived stem cells are being considered for similar uses and are in Phase III clinical trial for critical limb ischemia by Israel's Pluristem Therapeutics. (biomedcentral.com)
  • We have chosen to concentrate on the emerging therapeutics that broadly involves a wide range of cell types in clinical trials registered on the National Institutes of Health's clinical trials web site. (biomedcentral.com)
20196
Undergo1
  • In preparation for receipt of the stem cells, recipients undergo myeloablation to eliminate their own myeloid cells. (medscape.com)
Outcomes1
  • Increased access to transplant, reduced toxicity and relapse are improving patient outcomes. (bvsalud.org)
Treatments1
  • While companies like BlueRock Therapeutics L.P . are exploring allogeneic treatments, Aspen was able to break into the autologous space thanks to its genomic tools, co-founder and CSO Jeanne Loring told BioCentury. (blogspot.com)
Chronic2
  • Spinal Cord Stimulation for Chronic Abdominal Pain -- 20. (nshealth.ca)
  • When a patient is diagnosed with a blood cancer or chronic blood condition, it is often the start of a new journey that will be the beginning of great change. (rochester.edu)
Include1
  • This processing consists primarily of testing for infectious agents and determination of cell count but may include additional modifications or evaluations. (medscape.com)
Disease4
  • A San Diego firm that has $22 million worth of financial roots in the California stem cell agency this month snagged a bonus -- a ton of favorable attention for its efforts to treat Parkinson's disease. (blogspot.com)
  • Aspen is the only company taking an autologous approach to cell therapy for Parkinson's disease. (blogspot.com)
  • Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (harvard.edu)
  • Non-Myeloablative Transplant in Severe Sickle Cell Disease Is Safe & Effective. (ashpublications.org)
Leukemia1
  • [ 1 ] First described in 1848, MM is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance ( MGUS ) to plasma cell leukemia. (medscape.com)
Recipient1
Production1
  • The patient's own stored stem cells are then transfused into his/her bloodstream, where they replace destroyed tissue and resume the patient's normal blood-cell production. (wikipedia.org)
Units2
  • These cultured cells, or colony-forming units (CFUs), are coded according to the type of cells that they will ultimately produce (e.g. (nationalacademies.org)
  • Since then cord blood banking programs throughout the world have expanded rapidly (Broxmeyer, 1998), with the estimated number of units stored to date exceeding 155,000 (BMDW, 2004). (nationalacademies.org)
Diseases1
  • More research teams are accelerating the use of other types of adult stem cells, in particular neural stem cells for diseases where beneficial outcome could result from either in-lineage cell replacement or extracellular factors. (biomedcentral.com)
Specific1
  • These committed progenitor cells are difficult to discern from the original multipotent cells but can be cultured to form colonies of specific types of blood cells (Guyton and Hall, 2000). (nationalacademies.org)